Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts

American Journal of Epidemiology

Volumn 169, Issue 11, 2009, Pages 1378-1387

  Pinheiro, Simone P ^a,b,c   Tworoger, Shelley S ^b,c   Cramer, Daniel W ^b,c   Rosner, Bernard A ^b,c   Hankinson, Susan E ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anti inflammatory agents, non steroidal; Ovarian neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

COHORT ANALYSIS; DISEASE INCIDENCE; DOSE-RESPONSE RELATIONSHIP; DRUG; EPIDEMIOLOGY; HEALTH RISK; HEALTH SURVEY; HEALTH WORKER; HISTOLOGY; TUMOR; WOMENS HEALTH;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; RISK FACTOR;

ACETAMINOPHEN; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; UNITED STATES;

EID: 66249139240     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp062     Document Type: Article

References (52)

1. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999 ;91 (17): 1459-1467.
2. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum. 1997;26(6 suppl. 1):2 - 10.
3. Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998;47(suppl 2): S78-S87.
4. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120.
5. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5-6):255-258.
6. 2. Oncology. 2005;69(suppl 1):28-32.
7. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121(1 1): 2373-2380.
8. Denkert C, Köbel M, Pest S, et al. Expression of cyclooxy-genase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002;160(3):893-903.
9. Li S, Miner K, Fannin R, et al. Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium. Gynecol Oncol. 2004;92(2):622-627.
10. Ali-Fehmi R, Morris RT, Bandyopadhyay S, et al. Expression of cyclooxygenase-2 in advanced stage ovarian serous carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, and survival. Am J Obstet Gynecol. 2005; 192(3):819-825.
11. Khalifeh I, Munkarah AR, Lonardo F, et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol. 2004;23(2): 162-169.
12. Seo SS, Song YS, Kang DH, et al. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol. 2004;92(3):927-935.
13. Raspollini MR, Amunni G, Villanucci A, et al. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. Oncol Rep. 2004;11(2):309-313.
14. 1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene. 2003;22(54):8653-8661.
15. Song YC, Kim SH, Juhnn YS, et al. Apoptotic effect of celecoxib dependent upon p53 status in human ovarian cancer cells. Ann N Y Acad Sci. 2007; 1095:26-34.
16. Vital-Reyes V, Rodríguez-Burford C, Chhieng DC, et al. Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. Arch Med Res. 2006;37(6):689-695.
17. Xin B, Yokoyama Y, Shigeto T, et al. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and cigli-tazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer. 2007;110(4):791-800.
18. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, et al. Aspirin and epithelial ovarian cancer. Prev Med. 2001;33(6): 682-687.
19. Cramer DW, Harlow BL, Titus-Ernstoff L, et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998; 351(9096):104-107.
20. Moysich KB, Mettlin C, Piver MS, et al. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2001;10(8):903-906.
21. Tavani A, Gallus S, La Vecchia C, et al. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol. 2000; 11(9): 1171-1173.
22. Merritt MA, Green AC, Nagle CM, et al. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008;122(1):170-176.
23. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy. 2002;22(3):303-309.
24. Rosenberg L, Palmer JR, Rao RS, et al. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(9):933-937.
25. Schildkraut JM, Moorman PG, Halabi S, et al. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17(1): 104-107.
26. Fairfield KM, Hunter DJ, Fuchs CS, et al. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control. 2002;13(6):535-542.
27. Lacey JV Jr, Sherman ME, Hartge P, et al. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer. 2004;108(2):281-286.
28. Friis S, Sørensen HT, McLaughlin JK, et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88(5): 684-688.
29. Sørensen HT, Friis S, Nørgård B, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88(11): 1687-1692.
30. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev. 2005;5(5): 388-396.
31. Rockhill B, Willett WC, Hunter DJ, et al. Physical activity and breast cancer risk in a cohort of young women. J Natl Cancer Inst. 1998;90(15):1155-1160.
32. Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140(11): 1016-1019.
33. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119(5):837-839.
34. Cox DR. Regression models and life tables (with discussion). J R Stat Soc (B). 1972;34:187-220.
35. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3): 177-188.
36. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164(14):1519-1524.
37. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension. 2005;46(3):500-507.
38. Bonovas S, Filioussi K, Sitaras NM. Do nonsteroidal anti-inflammatory drugs affect the risk of developing ovarian cancer? A meta-analysis. Br J Clin Pharmacol. 2005;60(2): 194-203.
39. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006;17(7):871-888.
40. Scully RE. Classification of human ovarian tumors. Environ Health Perspect. 1987;73:15-24.
41. Baron JA, Sandler RS. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 2000;51:511-523.
42. Harris RE, Beebe-Donk J, Doss H, et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005;13(4):559-583.
43. Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001;83(3):575-585.
44. Gram IT, Braaten T, Adami HO, et al. Cigarette smoking and risk of borderline and invasive epithelial ovarian cancer. Int J Cancer. 2008;122(3):647-652.
45. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 1992;136(10):1204-1211.
46. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005;294(8):914-923.
47. Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004;140(3): 157-166.
48. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995; 333(10):609-614.
49. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348(10):891-899.
50. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC Trial. Gastroenterology. 2003; 125(2): 328-336.
51. Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology. 2008;134(1):29-38.
52. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006; 131 (6): 1674-1682.